# YF476 and Type II Gastric Carcinoids

> **NCT02454075** · PHASE2 · TERMINATED · sponsor: **Trio Medicines Ltd.** · enrollment: 3 (actual)

## Conditions studied

- Zollinger-Ellison Syndrome

## Interventions

- **DRUG:** YF476

## Key facts

- **NCT ID:** NCT02454075
- **Lead sponsor:** Trio Medicines Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2011-04-11
- **Primary completion:** 2012-06-22
- **Final completion:** 2012-06-22
- **Target enrollment:** 3 (ACTUAL)
- **Why stopped:** Poor recruitment
- **Last updated:** 2021-01-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02454075

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02454075, "YF476 and Type II Gastric Carcinoids". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02454075. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*